Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

NX-1607

Small molecule · Inhibitor of Casitas B-lineage lymphoma proto-oncogene-b (CBL-B) (CBLB) · developed by Nurix Therapeutics

Phase 1 Most advanced trial
NRIX Developer
1 Registered trials

What is NX-1607?

NX-1607 is an orally bioavailable small-molecule inhibitor of CBL-B, an E3 ubiquitin ligase that negatively regulates immune activation in leukocytes including T cells and NK cells. By inhibiting CBL-B, it is intended to promote NK cell and activated CD8+ T-cell infiltration of the tumor microenvironment. It is being studied in multiple solid tumors and lymphomas.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
Casitas B-lineage lymphoma proto-oncogene-b (CBL-B) (CBLB)
Mechanism
Inhibitor of Casitas B-lineage lymphoma proto-oncogene-b (CBL-B) (CBLB)
Pathways
immune activation, NK cell and CD8+ T-cell infiltration of the tumor microenvironment
Therapy area
Oncology
Developer
Nurix Therapeutics, Inc. (NRIX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05107674 Phase 1 Ovarian Cancer, Epithelial Recruiting NRIX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Cervical CancerDiffuse Large B Cell Lymphoma (DLBCL)Gastric CancerGastroEsophageal Junction (GEJ) CancerHead and Neck Squamous Cell CarcinomaMalignant Pleural Mesothelioma (MPM)Metastatic Castration-resistant Prostate Cancer (mCRPC)Metastatic or Unresectable MelanomaMetastatic Urothelial CarcinomaMicrosatellite Stable Colorectal CarcinomaNon-small Cell Lung Cancer (NSCLC)Ovarian Cancer, EpithelialRichter TransformationTriple Negative Breast Cancer (TNBC)

More from Nurix Therapeutics

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the NRIX page.

Follow NRIX, the company behind NX-1607

See NRIX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NRIX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.